Guideline Summary NGC-10323

Guideline Title
Management of chronic kidney disease.

Bibliographic Source(s)

Guideline Status
This is the current release of the guideline.

FDA Warning/Regulatory Alert
Note from the National Guideline Clearinghouse: This guideline references a drug(s) for which important revised regulatory information has been released.

- July 3, 2013 – Olmesartan Medoxomil: The U.S. Food and Drug Administration (FDA) is warning that the blood pressure drug Olmesartan Medoxomil (marketed as Benicar, Benicar HCT, Azor, Tribenzor, and generics) can cause intestinal problems known as sprue-like enteropathy. Symptoms of sprue-like enteropathy include severe, chronic diarrhea with substantial weight loss. FDA has approved changes to the labels of these drugs to include this concern. Sprue-like enteropathy has not been detected with angiotensin receptor blocker (ARB) drugs other than olmesartan.

Scope

Disease/Condition(s)
Chronic kidney disease (CKD)

Note: CKD is kidney damage for ≥3 months, defined by structural or functional abnormalities of the kidney, with or without decreased glomerular filtration rate (GFR)

Guideline Category
Diagnosis
Management
Screening
Treatment

Clinical Specialty
Cardiology
Internal Medicine
Nephrology
Preventive Medicine

Intended Users
Advanced Practice Nurses
Nurses
Physician Assistants
Physicians

Guideline Objective(s)
- To identify populations that may benefit from more systematic screening for chronic kidney disease (CKD) and provide an overview of methods for screening and diagnosis
To outline treatment options for patients with CKD to decrease progression of renal deterioration and potentially decrease morbidity and mortality

To highlight common co-morbid conditions such as cardiovascular disease (CVD) and diabetes, emphasizing the importance of aggressive management of these conditions to potentially decrease morbidity and mortality among patients with CKD

**Target Population**

Adults with chronic kidney disease (CKD)

**Interventions and Practices Considered**

**Diagnosis**

1. Screening for microalbuminuria (patients with diabetes)
2. Screening for chronic kidney disease (CKD) (patients with increased risks)
3. Laboratory studies
   - Glomerular filtration rate (GFR)
   - Urine studies for albuminuria
4. Ultrasound Imaging

**Treatment**

1. Angiotensin converting enzyme inhibitor (ACEI) or an angiotensin receptor blocker (ARB)
2. Blood pressure control
3. Management of comorbid diabetes and consideration of cardiovascular risk factors
4. Monitoring for CKD complications (anemia, electrolyte abnormalities, abnormal fluid balance, mineral bone disease, and malnutrition)
5. Avoidance of nephrotoxic medications
6. Follow-up
   - Yearly assessment of GFR and albuminuria
   - Referral to nephrology (if indicated)

**Major Outcomes Considered**

- Kidney damage
- Disease progression
- End stage renal disease (ESRD)
- Cardiovascular disease (CVD)
- Morbidity and mortality

**Methodology**

**Methods Used to Collect/Select the Evidence**

Searches of Electronic Databases

**Description of Methods Used to Collect/Select the Evidence**

**Strategy for Literature Search**

The team began the search of literature by accepting the results of the literature searches performed for fairly recent systematic reviews:


To update those searches with more recent literature and to examine literature on other topics, a systematic search of literature on MEDLINE was performed.

The major search terms were: "chronic kidney disease excluding end stage renal disease"; time frame started with 1/1/07 unless a more recent review (above) addressed the topic; type of publication was guidelines, controlled trials (including meta-analyses), and cohort studies; population was human/adult; and language was English.

Within those parameters, individual searches were performed for the following topics: screening; assessment of renal
Within these parameters individual searches were performed for the following topics: screening, assessment of renal function/staging; history and symptoms; physical exam; laboratory tests; imaging; renin-angiotensin system blockade (ACEI, ARB, optimizing blood pressure, reducing albuminuria, inhibition of renal fibrosis); treatment of diabetes mellitus and of hypertension; management of dyslipidemia, smoking, and aspirin therapy; management of anemia, mineral bone disease, metabolic acidosis, potassium and sodium balance, fluid balance/volumes management, and malnutrition; dietary recommendations (sodium, protein, malnutrition), medication dose adjustment/medications to avoid/nephrotoxic medications; psychiatric disorders (depression); sleep quality and sleep disorders; sexual dysfunction, monitoring and follow-up; pregnancy, geriatrics, minorities, and other results for the major search terms not included in the above specific searches. The specific search strategy is available upon request.

The search was conducted in components each keyed to a specific causal link in a formal problem structure, which is available upon request. The search was supplemented with very recent clinical trials known to expert members of the panel. Negative trials were specifically sought. The search was a single cycle.

**Number of Source Documents**

Not stated

**Methods Used to Assess the Quality and Strength of the Evidence**

Weighting According to a Rating Scheme (Scheme Given)

**Rating Scheme for the Strength of the Evidence**

**Levels of Evidence**

A. Randomized controlled trials

B. Controlled trials, no randomization

C. Observational trials

D. Opinion of expert panel

**Methods Used to Analyze the Evidence**

Review of Published Meta-Analyses

Systematic Review

**Description of the Methods Used to Analyze the Evidence**

Not stated

**Methods Used to Formulate the Recommendations**

Expert Consensus

**Description of Methods Used to Formulate the Recommendations**

Conclusions were based on prospective randomized clinical trials if available, to the exclusion of other data; if randomized controlled trials were not available, observational studies were admitted to consideration. If no such data were available for a given link in the problem formulation, expert opinion was used to estimate effect size.

**Rating Scheme for the Strength of the Recommendations**

**Strength of Recommendation**

I. Generally should be performed

II. May be reasonable to perform

III. Generally should not be performed

**Cost Analysis**

- A recent cost-effectiveness analysis concluded that annual urine dipstick testing for albuminuria in patients with diabetes or hypertension, as well as those aged 55 years and older without concurrent diabetes or hypertension, was cost-effective.

- A recent Kidney Disease: Improving Global Outcomes (KDIGO) guideline suggests statin + ezetimibe as an alternative to statin monotherapy, especially in patients with an estimated glomerular filtration rate (eGFR) ≤60 ml/min/1.73 m² (e.g., g3a-5). In clinical practice, this approach may be limited by the higher cost of ezetimibe compared with statin monotherapy.

**Method of Guideline Validation**

Internal Peer Review

**Description of Method of Guideline Validation**

Drafts of this guideline were reviewed in clinical conferences and by distribution for comment within departments and divisions of the University of Michigan Medical School to which the content is most relevant: Family Medicine, General Medicine, and Nephrology. The final version was endorsed by the Clinical Practice Committee of the University of Michigan Faculty Group Practice and the Executive Committee for Clinical Affairs of the University of Michigan Hospitals and Health Centers.
Recommendations

Major Recommendations

**Note from the University of Michigan Health System (UMHS) and the National Guideline Clearinghouse (NGC):** The following guidance was current as of 2014. Because UMHS occasionally releases minor revisions to its guidance based on new information, users may wish to consult the original guideline document for the most current version.

**Note from NGC:** The following key points summarize the content of the guideline. Refer to the full text of the original guideline document for detailed information on each of the screening procedures.

The strength of recommendation (I-III) and levels of evidence (A-D) are defined at the end of the "Major Recommendations" field.

**Background**
- Despite increasing prevalence of chronic kidney disease (CKD), it is often under-recognized and under-treated. [A]
- Evidence for screening and management of early stage CKD is limited due to absence of large randomized controlled trials.

**Definition and Staging** (see Table 1 and Table 2 in the original guideline document)
Kidney damage for ≥3 months, defined by structural or functional abnormalities of the kidney, with or without decreased glomerular filtration rate (GFR)

**Diagnosis**
- Screen patients with diabetes annually for microalbuminuria if not on an angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) and for creatinine and estimated GFR [IA]. Consider screening for CKD among patients at increased risk, especially those with hypertension [IA] and patients aged >55 years. [IID]
- Laboratory studies needed to diagnose and stage CKD include an assessment of GFR (usually estimated by the Modification in Diet and Renal Disease Study [MDRD] equation) and urine studies for the presence or absence of albuminuria. [IC]
- Ultrasound imaging for structural kidney disease may also be helpful in certain populations. [IID]

**Treatment**
- Blockade of the renin angiotensin aldosterone system with either an ACEI or an ARB is the cornerstone of treatment to prevent or decrease the rate of progression to end stage renal disease. [IA]
- Blood pressure control (<140/90) reduces renal disease progression and cardiovascular morbidity and mortality. Current evidence does not support stricter blood pressure control targets for the majority of patients with CKD [IA]. CKD patients with albuminuria may benefit from tighter control with a target of <130/80 [IIA].
- Optimally manage comorbid diabetes and address cardiovascular risk factors to decrease risk for cardiovascular disease – the leading cause of mortality for patients with CKD. [IA] Statin or statin/ezetimibe therapy is recommended in all CKD patients age ≥50 years to decrease the risk of cardiovascular or atherosclerotic events. [IA]
- Monitor for other common complications of CKD including: anemia, electrolyte abnormalities, abnormal fluid balance, mineral bone disease, and malnutrition. [ID]
- Avoid nephrotoxic medications to prevent worsening renal function. [ID]

**Monitoring and Follow Up**
- The timing and frequency of CKD monitoring and follow up depends on disease severity and risk for progression; GFR and albuminuria should be assessed a minimum of once per year. [ID] (see Table 6 in the original guideline document)
- Refer CKD stage G4 or G5 (see Table 2 in the original guideline document) to nephrology for co-management and preparation for renal replacement therapy. Consider referral at earlier stage to assist with diagnosis of underlying cause and/or treatment of common complications of CKD. [IC]

**Definitions:**

**Levels of Evidence**
- A. Randomized controlled trials
- B. Controlled trials, no randomization
- C. Observational trials
- D. Opinion of expert panel

**Strength of Recommendation**
- I. Generally should be performed
- II. May be reasonable to perform
- III. Generally should not be performed

**Clinical Algorithm(s)**
- None provided

**Evidence Supporting the Recommendations**
Type of Evidence Supporting the Recommendations

The type of supporting evidence is identified and graded for each recommendation (see the "Major Recommendations" field).

Conclusions were based on prospective randomized clinical trials (RCTs) if available, to the exclusion of other data. If RCTs were not available, observational studies were admitted to consideration. If no such data were available for a given link in the problem formulation, expert opinion was used to estimate effect size.

Benefits/Harms of Implementing the Guideline Recommendations

Potential Benefits

Appropriate management of chronic kidney disease (CKD) to delay and prevent life-threatening adverse outcomes

Potential Harms

- Many herbs can potentially interact with prescription medications or cause additional kidney damage in patients with underlying chronic kidney disease (CKD).
- In certain CKD populations, including the elderly and those with diabetes mellitus, aggressive blood pressure control could lead to negative outcomes such as acute deterioration in kidney function, increased risk for cardiovascular events and orthostatic hypotension.

See Table 7 in the original guideline document for adverse effects associated with common agents for renin angiotensin aldosterone blockade used in treatment for CKD.

Statin

- Recent studies have provided conflicting evidence regarding the benefit of statins among patients with end stage renal disease (ESRD) receiving renal replacement therapy. Some of the studies have demonstrated an increased risk of cerebrovascular events among dialysis patients taking statins.
- The use of standard doses of statins appears safe among most patients with CKD and does not require special monitoring beyond that for non-CKD patients. More intensive statin regimens have not been well studied in patients with CKD and there is concern that this population is at higher risk for adverse events related to the medication.
- For patients with CKD G1-G2, the only exception to statin drugs used in the general population is that 40 mg of rosuvastatin daily is not recommended because of potential increased risk for adverse renal event.

Contraindications

Contraindications

- Eplerenone (Inspra) is contraindicated in patients with serum creatinine (Scr) ≥ 2 mg/dL (males) or ≥ 1.8 (females) due to increased risk of hyperkalemia.
- Clinicians should be aware that angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are contraindicated in pregnancy (category X, known to cause birth defects).

Qualifying Statements

These guidelines should not be construed as including all proper methods of care or excluding other acceptable methods of care reasonably directed to obtaining the same results. The ultimate judgment regarding any specific clinical procedure or treatment must be made by the physician in light of the circumstances presented by the patient.

Implementation of the Guideline

Description of Implementation Strategy

An implementation strategy was not provided.

Implementation Tools

Patient Resources

Staff Training/Competency Material

For information about availability, see the Availability of Companion Documents and Patient Resources fields below.

Institute of Medicine (IOM) National Healthcare Quality Report Categories

IOM Care Need

Getting Better

Living with Illness
Staying Healthy

IOM Domain
Effectiveness
Patient-centeredness

Identifying Information and Availability

Bibliographic Source(s)

Adaptation
Not applicable: The guideline was not adapted from another source.

Date Released
2014 Mar

Guideline Developer(s)
University of Michigan Health System - Academic Institution

Source(s) of Funding
University of Michigan Health System

Guideline Committee
Chronic Kidney Disease Guideline Team

Composition of Group That Authored the Guideline

Team Leader: Jennifer Reilly Lukela, MD, General Medicine

Team Members: R. Van Harrison, PhD, Medical Education; Masahito Jimbo, MD, Family Medicine; Ahmad Mahallati, MD, Nephrology; Rajiv Saran, MBBS, Nephrology; Annie Z. Sy, PharmD, Quality Management Program

Ambulatory Clinical Guidelines Oversight: Grant Greenberg, MD, MA, MHSA; R. Van Harrison, PhD

Financial Disclosures/Conflicts of Interest
The University of Michigan Health System endorses the Guidelines of the Association of American Medical Colleges and the Standards of the Accreditation Council for Continuing Medical Education that the individuals who present educational activities disclose significant relationships with commercial companies whose products or services are discussed. Disclosure of a relationship is not intended to suggest bias in the information presented, but is made to provide readers with information that might be of potential importance to their evaluation of the information.

<table>
<thead>
<tr>
<th>Team Member</th>
<th>Company</th>
<th>Relationship</th>
</tr>
</thead>
<tbody>
<tr>
<td>R Van Harrison, PhD</td>
<td>(none)</td>
<td></td>
</tr>
<tr>
<td>Jennifer R Lukela, MD</td>
<td>(none)</td>
<td></td>
</tr>
<tr>
<td>Masahito Jimbo, MD</td>
<td>(none)</td>
<td></td>
</tr>
<tr>
<td>Ahmad Mahallati, MD</td>
<td>(none)</td>
<td></td>
</tr>
<tr>
<td>Rajiv Saran, MBBS</td>
<td>Forest, Renal Research Institute Research funding</td>
<td>(none)</td>
</tr>
<tr>
<td>Annie Z. Sy, PharmD</td>
<td>(none)</td>
<td></td>
</tr>
</tbody>
</table>

Guideline Status
This is the current release of the guideline.

Guideline Availability
Electronic copies: Available from the University of Michigan Health System Web site.

Availability of Companion Documents
Continuing Medical Education (CME) Information is available from the University of Michigan Health System Web site.

Patient Resources
The following are available:


Please note: This patient information is intended to provide health professionals with information to share with their patients to help them better understand their health and their diagnosed disorders. By providing access to this patient information, it is not the intention of NGC to provide specific medical advice for particular patients. Rather we urge patients and their representatives to review this material and then to consult with a licensed health professional for evaluation of treatment options suitable for them as well as for diagnosis and answers to their personal medical questions. This patient information has been derived and prepared from a guideline for health care professionals included on NGC by the authors or publishers of that original guideline. The patient information is not reviewed by NGC to establish whether or not it accurately reflects the original guideline's content.

NGC Status

This NGC summary was completed by ECRI Institute on May 16, 2014.

Copyright Statement

This NGC summary is based on the original guideline, which is copyrighted by the University of Michigan Health System (UMHS).

Disclaimer

NGC Disclaimer

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at http://www.guideline.gov/about/inclusion-criteria.aspx.

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.